Business Context and Reporting Period
Company: ILLUMINA, INC. (ILMN)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Fiscal Quarter ended June 29, 2025 (Q2 2025)
Business Overview: Illumina is a global leader in DNA sequencing and array-based technologies serving research, clinical, and applied markets. Following the spin-off of GRAIL in June 2024, the company now operates as a single reportable segment, "Core Illumina."
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $1,059 | $1,112 | $2,100 | $2,188 |
| Gross Profit | $695 | $721 | $1,378 | $1,388 |
| Gross Margin | 65.6% | 64.8% | 65.6% | 63.5% |
| Operating Income | $214 | ($1,637) | $378 | ($1,749) |
| Net Income | $235 | ($1,988) | $366 | ($2,114) |
| Diluted EPS | $1.49 | ($12.48) | $2.31 | ($13.28) |
| Cash & Equivalents | $934 | $1,127 | $934 | $1,048 |
| Short-term Investments | $221 | $93 | $221 | $93 |
| Total Debt (Principal) | $2,000 | $2,000 | $2,000 | $2,000 |
| Operating Cash Flow (YTD) | $474 | $157 | $474 | $157 |
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability with $235 million in net income for Q2 2025, a significant improvement from a $1,988 million net loss in Q2 2024. This shift is primarily attributable to the absence of the $1.886 billion goodwill and intangible impairment charge recorded in the prior year related to the GRAIL segment.
- Revenue Decline: Total revenue decreased 5% year-over-year in Q2 2025 ($1,059 million vs. $1,112 million). The decline was driven by a 16% drop in instrument revenue due to fewer shipments of high- and mid-throughput sequencing instruments and a 6% decrease in service revenue.
- Operating Expenses: Total operating expenses decreased significantly to $481 million in Q2 2025 from $2,358 million in Q2 2024. Excluding the prior year's impairment charges, Core Illumina operating expenses increased slightly due to lower net gains on contingent consideration liabilities related to GRAIL.
- Share Repurchases: The company repurchased $384 million of common stock in Q2 2025 under a $1.5 billion authorization program, with approximately $804 million remaining available.
Guidance, Outlook, and Risks
- Pending Acquisition: On June 22, 2025, Illumina agreed to acquire SomaLogic and certain assets from Standard BioTools for $350 million in cash, plus potential milestone payments up to $75 million. The transaction is expected to close in the first half of 2026, subject to regulatory approvals.
- Tariff Impact: New tariffs enacted in April 2025 are impacting costs, particularly regarding imports from Singapore. Management expects to partially mitigate these impacts in 2025 through supply chain optimization and pricing actions, aiming for full mitigation in 2026.
- China Regulatory Risk: Illumina was added to China's "unreliable entities list" in Q1 2025 and is prohibited from exporting sequencing instruments to China. This continues to negatively impact revenue in the Greater China region.
- Legal Proceedings: The company settled a False Claims Act investigation with the U.S. Department of Justice for $9.8 million plus interest. Multiple shareholder derivative lawsuits regarding the GRAIL acquisition remain pending, though one action was settled in principle with no payment required.
- Tax Outlook: Management anticipates a decrease in the effective tax rate starting in Q3 2025 due to recent U.S. tax legislation changes regarding the capitalization of R&D expenses.
Investor Verification Checklist
- China Exposure: Verify the specific revenue impact of the export ban on sequencing instruments in China and the effectiveness of mitigation strategies.
- SomaLogic Acquisition: Monitor regulatory approval progress for the $350 million SomaLogic acquisition and potential integration costs.
- Tariff Mitigation: Assess the company's ability to pass tariff-related cost increases to customers without further eroding demand.
- GRAIL Contingent Liabilities: Review the fair value assumptions for the GRAIL contingent value rights (CVRs), which remain a variable expense item.
- Instrument Demand: Evaluate the sustainability of the decline in high-throughput instrument shipments and the transition to the NovaSeq X platform.